Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer | Zendy

Vivian Goodell | Zendy; Lupe G. Salazar | Zendy; Nicole Urban | Zendy; Charles W. Drescher | Zendy; Heidi J. Gray | Zendy; Ron E. Swensen | Zendy; Martin McIntosh | Zendy; Mary L. Disis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer

Author(s) -

Vivian Goodell,

Lupe G. Salazar,

Nicole Urban,

Charles W. Drescher,

Heidi J. Gray,

Ron E. Swensen,

Martin McIntosh,

Mary L. Disis

Publication year - 2006

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.03.2813

Subject(s) - ovarian cancer , medicine , antibody , immunity , antigen , immunology , immune system , cancer , humoral immunity , oncology

Presence of intratumoral T-cell infiltration has been linked to improved survival in ovarian cancer patients. We questioned whether antibody immunity specific for ovarian cancer tumor antigens would predict disease outcome. We evaluated humoral immune responses against ovarian cancer antigens p53, HER-2/neu, and topoisomerase IIalpha.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research